# Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma

> **NCT00082888** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 93 (actual)

## Conditions studied

- Anaplastic Large Cell Lymphoma
- Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Nodal Marginal Zone Lymphoma
- Recurrent Adult Hodgkin Lymphoma
- Recurrent Adult T-Cell Leukemia/Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Small Lymphocytic Lymphoma
- Splenic Marginal Zone Lymphoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Tipifarnib

## Key facts

- **NCT ID:** NCT00082888
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03-24
- **Primary completion:** 2009-05-20
- **Final completion:** 2017-07-05
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2020-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00082888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00082888, "Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00082888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*